HIV-1 infection results in long-lasting activation of the immune system including elevated production of pro-inflammatory cytokine/chemokines, and bacterial product release from gut into blood and tissue compartments, which are not fully restored by antiretroviral therapies. HIV-1 has also developed numerous strategies via viral regulatory proteins to hijack cell molecular mechanisms to enhance its own replication and dissemination. Here, we reviewed the relationship between viral proteins, immune activation/inflammation, and deregulated metabolism occurring in HIV-1-infected patients that ultimately dampens the protective innate and adaptive arms of immunity.
significantly reduced, but fails to normalize IDO-1 activity to levels observed within the control uninfected subjects [65, 67, 68] , recent data provided by Jenabian M-A. et al.
show full normalization of IDO-1 activity in ART recipients with their cohorts of subjects [11] . This discrepancy is likely to be due the fact that last study included infected subjects who initiated ART within the first weeks of the primary infection, thus underscoring the benefit of early treatments to restore proper tryptophan metabolism. The CD4 T-cell proliferation by inducing IDO-1 in myeloid and plasmacytoid dendritic cells (pDC), an effect that is partially prevented by the use of IDO-1 competitive blocker 1methyl tryptophan (1MT) [54, 57, 72, 73] . Furthermore IDO-1 signaling pathway is essential for pDC-mediated T reg generation from CD4 T-cells and implicates the generation of Kyn and other Tryp catabolites as the critical factors of this process [74] .
The increased Tryp catabolism observed in HIV-1-infected humans and SIV-infected macaques also correlates with the loss of Th 17 cells, important players in mucosal immunity, thus changing the balance of Th 17 to T reg and increasing immuno-suppressive responses [61, 63, [75] [76] [77] . Interestingly, a small group of HIV-1-infected subjects, called elite controllers (EC) who are able to spontaneously control viral replication and to display normal CD4 counts in the absence of ART [78] , show similar IDO-1 activity compared to uninfected subjects [63] . This confirms the key role of Tryp metabolism in HIV-1 control and the maintenance of proper T-cell response [63] . Furthermore, increased IDO-1 activity in primary HIV-1-infected patients correlates positively with the levels of CD8 T-cell activation [11] .
B. Innate immunity. In diverse anatomical compartments such as gut, lymph nodes and blood, the early induction of IDO-1 activity in macrophages, and dendritic cells dampens the antiviral responses and thus contributes to disease progression in SIV and HIV infections [52, 77, 79] . Elevated IDO-1 activity during primary infection positively correlates with monocytic pro-inflammatory cytokines including IL-6, IL-18, and TNF-, and negatively with the frequency of dendritic cells [11] . Furthermore, increasing observations indicate that HIV-1 and SIV-1 infections mediate heightened production of toxic metabolites such as Kyn and quinolinic acids by brain-resident macrophages, contributing to the neuron/astrocyte cell death, and the neuropathogenesis of HIVassociated dementia (HAD) and HIV-associated myelopathy (HAM) [80] [81] [82] .
Increased glucose metabolic activity during HIV-1 infection

Glucose management, a key factor for bioenergetic needs, is deregulated in HIV-1
infection. Glucose is readily utilized by cells of the immune system and is used to generate energy and biosynthetic precursors. Activation of immune cells is associated with increased glucose utilization and this is facilitated, in part, by increased expression of glucose transporters [83] . For instance, T-cell activation requires the up-regulation of glycolysis (catabolism of glucose) to meet the biosynthetic and bioenergic needs of cell proliferation, survival, and immune function including the synthesis of cytokines [2, 5, 84] . As mentioned earlier, since HIV-1 infection is characterized by long-lasting and excessive inflammation/cell activation, most of infected patients display up-regulation in glucose metabolic activity [6, [85] [86] [87] [88] . These observations are consistent with higher glucose uptake/trafficking in HIV-1-infected patients and elevated metabolite pool sizes such as sedoheptulose 7-phosphate and ribose-phosphate [86] .
High glucose up-take in CD4 T-cells enhances cell permissiveness to HIV-1. HIV-1
infection causes an increase in glycolytic flux which brings the glycolytic capacity of primary infected CD4 T-cells close to its maximum [89] . The study shows that glycolysis is particularly required for virion production and additionally worsens the sensitivity of the infected cell to virus-induced apoptosis. Palmer C.S. et al. recently reported significant increase in the percentage of circulating CD4 T-cells expressing Glut-1 (major glucose transporter on T-cells) which is associated with cell activation and depletion during chronic HIV-1 infection and is not fully diminished following combination antiretroviral therapies [88] . Interestingly, IL-7 stimulation renders CD4 T-cells susceptible to HIV-1 entry by up-regulating the surface expression of Glut-1 and glucose transport into T-cells [90] . Hyperglycemia (condition with excessive amounts of glucose in plasma) also has the potential to enhance HIV-1 entry into T-cells through the upregulation of CXCR4 expression [91] . Taylor H.E. et al. have shown that phospholipase D1 links T-cell activation signals to increased permissiveness to HIV-1 by triggering specific transcriptional programs involving glucose uptake and nucleotide synthesis [92] .
Protection of infected macrophages by counteracting glucose metabolism. In contrast
to infected CD4 T-cells, HIV-1-producing macrophages has significant reductions in glucose uptake and steady glycolytic intermediates [86] . The viral protein Vpr, protects infected macrophages from apoptosis by the inhibition of hexokinase-1 (HK-1) activity, an enzyme that converts glucose to glucose-6-phosphate, therefore playing a nonmetabolic role in maintaining mitochondrial integrity [93, 94] . HIV-1 Vpr can also hijack several pathways related to glucose management by inducing the expression of HK-1, glucose-6-phosphate dehydrogenase, and pyruvate kinase muscle type 2 [95] . 
Deregulation of lipid metabolism and compositions
Foxo3a: potential candidate to explain deregulated immuno-metabolism in HIV-
1.
Forkhead box O 3a (Foxo3a) is a transcriptional factor constitutively expressed on hematopoietic cells. In addition to pro-apoptotic and anti-proliferative targets, active Foxo3a induces the transactivation of genes implicated in the ROS detoxification (SOD, catalase) [79, 108, 109] , and genes regulating glucose metabolism (glucose-6phosphatase) [110, 111] . Although we and others have shown that HIV-1-infected individuals display up-regulation in Foxo3a activity in infected macrophages, memory CD4 T-, and B-cells, even under ART, this leads to the expression of pro-apoptotic targets such as Bim, FasL, and TRAIL rather than metabolism-related genes [112] [113] [114] .
However, the viral protein Vpr inhibits the ability of hypoglycemic peptide hormone insulin to suppress the transcriptional expression of glucose-6-phosphatase and SOD by inhibiting forkhead transcriptional factor (Foxo) activity in hepatocytes [115, 116] .
Neurons undergo massive Foxo3a-dependent apoptosis in the presence of TNF- and high glucose concentrations, conditions usually observed in infected patients developing HAD and HAND [117] .
Modulation of autophagy in HIV-1 infection.
Physiologic functions and impact on T-cells during HIV-1 infection.
Autophagy represents the basic catabolic mechanism that involves degradation of unnecessary or dysfunctional cellular components through the actions of specialized lysosomal structures called autophagosomes. The role of autophagy consists of degrading damaged or aged organelles, protein aggregates, but is also involved in microbial defence, antigen processing, and lymphocyte development and function [118] [119] [120] .
Activation of autophagy occurs in response to nutrient deprivation, and recognition of pathogen associated patterns including HIV-1-related molecules [121] [122] [123] [124] . In contrast to productively infected T lymphocytes, HIV-1-infected cells can induce autophagy in bystander uninfected CD4 T-cells through HIV-1 Gp120 exposure, leading to caspasedependent apoptosis and cell depletion [126] [127] [128] [129] . Interestingly, blood cells from HIV-1infected elite controller subjects display more efficient autophagic response that leads to a reduced viral production, thus confirming key role of autophagy in long-term immune protection against accelerated HIV-1-mediated disease progression [125] . autophagocytosis-associated protein 3; Atg-3) and inhibits the formation of autophagosomes in macrophages, dampening the anti-HIV-1 mechanism in these cells [131] [132] [133] .
Potential strategies to restore proper immuno-metabolism in infected patients.
It now is well recognized by the scientific community that a large proportion of HIV-1infected individuals, including those receiving ART treatment, can experience profound deregulations in immune-metabolism. Some of these metabolic defects may take place as early as the first weeks of primary infection, and might be reversed if ART is initiated during this early phase of infection [11] . However, ART usually improves, but does not always normalize all metabolic and clinical parameters (e.g. glucose uptake and gut inflammation) [12, 15, 88, 134] . Moreover, the long-term administration of antiretroviral molecules per se, particularly anti-proteases, results in abnormal fat distribution and impaired glucose homeostasis in more than 50% of treated patients [135] [136] [137] [138] . Therefore it is critically needed to develop new strategies aiming to improve metabolic conditions in HIV-1-infected patients in order to enhance innate and adaptive protective immunity.
The wise old saying, we are what we eat, may be particularly true in the context of immune fight against HIV-1. Although there is no clear evidence of beneficial effects of diets on premature immune ageing during chronic HIV-1-infection, the use of antioxidant vitamins, minerals, amino acids, and other dietary supplements is widespread in the HIVinfected community. Furthermore, enhancing the lifestyle represents another first-line approach, with a focus on smoking cessation in addition to exercise and diet modification (Mediterranean-style dietary pattern) to decrease cholesterol and triglyceride levels in HIV-1-infected patients [139] [140] [141] [142] . Metformin and thiazolidinediones, molecules used to treat type 2 diabetes, have been shown to significantly improve glucose management, and prevent atherosclerosis in HIV-1 patients [143] [144] [145] . The in vivo administration of antioxidant N-acetylcystein amide or gene delivery of antioxidant enzymes is effective in protecting the blood brain barrier from oxidative stress-and inflammation-induced damage in Gp120-or Tat-exposed animals, and thus could be a viable therapeutic option for patients with HAD [41, 42, 146] . Similarly, the treatment of mice with 1-MT significantly inhibits IDO-1 activity, and enhance the elimination of virus-infected macrophages in an in vivo model of HAD [82] . In SIV-1-infected rhesus macaques, 1-MT synergizes with ART in inhibiting viral replication without interference with the beneficial immunologic effects of the antiretroviral treatment [147] . The administration of Niacin, a B vitamin, has shown encouraging preliminary results in reducing cholesterol and LDL, and reducing the levels of the up-stream Kyn in HIV-1-infected patients [148, 149] . A randomized trial is currently in progress to fully evaluate the potential benefit of oral extended-release niacin in reducing immune activation, increasing CD4 T-cell recovery, and improving neurocognitive function in ART recipients [150] .
Conclusion.
Despite the significant advances in HIV treatments and the reduction of both mortality and morbidity associated with infection, it is largely believed that current regimens cannot achieve HIV cure. This necessitates the implementation of complementary approaches by switching towards unconventional concepts. In this regard, there is now a growing evidence that deregulated immuno-metabolism represents a central element to the biased immunity against HIV-1 infection that leads to viral dissemination and pathogenesis. Understanding these immuno-metabolic defects in a timely manner and identifying novel biomarkers that can either predict or reflect their outcome is then a critical need in the fight against HIV and its associated clinical complications. This will ultimately pave the way to find innovative approaches to counteract these defects and reduce cell activation and chronic inflammation that will likely prevent massive T-cell loss and reinforce anti-HIV-1 defence and eventually achieve HIV cure. Higher levels of tryptophan metabolism mediated by interaction of CTLA-4 (expressed by T-cells) with its ligands (B7-1 and B7-2) expressed by antigen presenting cells is also associated with profound effects in T-cell activation, cytokine production, proliferation and differentiation. Jurkat cells H2O2 / ↑(TNF-; Nf-B; TAK1; AP-1) ↑HIV-1 LTR activation yes [25] ; [30] CD4 + MAGI cells Tat ↑(H2O2); ↓(GSH) ↑(Nrf2; Nox2; AKT; Nf-B) ↑HIV-1 LTR activation yes [27] ; [28] CD8; memory CD4
T-cells 
